TMP-SMX safety concerns include which of the following?

TMP-SMX safety concerns include which of the following?

• A. Hyperkalemia, cytopenias, and renal function concerns
• B. Hypokalemia only
• C. Hypertension only
• D. Hyperglycemia only

Answer: (A)

TMP-SMX safety concerns center on potassium handling, blood cell production, and kidney function. The trimethoprim component can act like a potassium-sparing drug in the distal nephron, reducing potassium excretion and raising the risk of hyperkalemia, especially in older adults, those with kidney disease, or patients taking other potassium-raising meds. Clinically this matters because high potassium can cause dangerous heart rhythm changes, so potassium levels should be checked when starting therapy and monitored during treatment as needed. The folate antagonism by trimethoprim can impair DNA synthesis in rapidly dividing cells, including bone marrow, leading to cytopenias (low red cells, white cells, and/or platelets). This risk is higher in patients with existing marrow suppression or when combined with other myelosuppressive drugs. Monitoring a complete blood count helps detect this early, and therapy may need to be adjusted if cytopenias develop. Renal function concerns include rises in creatinine and potential nephrotoxicity, such as interstitial nephritis or crystal-induced kidney injury, especially with dehydration or preexisting kidney disease. Ensuring adequate hydration, avoiding other nephrotoxics, and monitoring renal function are important during therapy. These safety issues—hyperkalemia, cytopenias, and renal function changes—make up the primary concerns with TMP-SMX. The other options (hypokalemia, hypertension, hyperglycemia) are not typical or primary adverse effects of this medication.

TMP-SMX safety concerns center on potassium handling, blood cell production, and kidney function. The trimethoprim component can act like a potassium-sparing drug in the distal nephron, reducing potassium excretion and raising the risk of hyperkalemia, especially in older adults, those with kidney disease, or patients taking other potassium-raising meds. Clinically this matters because high potassium can cause dangerous heart rhythm changes, so potassium levels should be checked when starting therapy and monitored during treatment as needed.

The folate antagonism by trimethoprim can impair DNA synthesis in rapidly dividing cells, including bone marrow, leading to cytopenias (low red cells, white cells, and/or platelets). This risk is higher in patients with existing marrow suppression or when combined with other myelosuppressive drugs. Monitoring a complete blood count helps detect this early, and therapy may need to be adjusted if cytopenias develop.

Renal function concerns include rises in creatinine and potential nephrotoxicity, such as interstitial nephritis or crystal-induced kidney injury, especially with dehydration or preexisting kidney disease. Ensuring adequate hydration, avoiding other nephrotoxics, and monitoring renal function are important during therapy.

These safety issues—hyperkalemia, cytopenias, and renal function changes—make up the primary concerns with TMP-SMX. The other options (hypokalemia, hypertension, hyperglycemia) are not typical or primary adverse effects of this medication.